SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing extreme volatility and trending due to a massive short squeeze, with the stock price surging dramatically this week. The community is actively discussing potential price targets, expressing both excitement and disbelief at the rapid gains, and debating whether the surge is sustainable or a potential bubble. Some traders are drawing comparisons to other high-flying stocks and are looking for similar opportunities.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation of acquiring Warner Bros. Discovery, with discussions centering on the potential benefits of consolidating content libraries and HBO's subscriber base. However, the community is also weighing potential regulatory hurdles, debt implications, and the impact on market competition, with some viewing the deal as an overreach.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition, with Netflix reportedly submitting a mostly cash bid, fueling a bidding war against Paramount and Comcast. Community chatter revolves around potential deal structures, regulatory hurdles, and whether a higher bid will emerge. Some traders speculate on potential outcomes for shareholders depending on the final deal.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TREASURE GLOBAL INC ($TGL) is trending due to its recent volatility and discussions around a potential short squeeze, driven by a low float and high borrowing fees. The community is actively debating the impact of a possible reverse stock split and monitoring for news related to AI initiatives and partnerships that could drive the price higher. Comparisons to previous runners like $SMX are common, with some anticipating a similar explosive move.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders weigh the possibility of a December rate cut by the Federal Reserve amid mixed signals and a recent government shutdown impacting economic data releases. Community members are actively discussing potential safe-haven assets and the impact of a 50-year mortgage proposal, with some anticipating a bond market rally while others remain bearish. The conversation also encompasses concerns about debt, economic strength, and shifting global dynamics influencing the long-term treasury bond ETF.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending as traders discuss its potential for a short squeeze, drawing comparisons to other recent low float runners like $SMX. The community is actively debating its low float and high short interest, while acknowledging the stock's history of volatility and reverse splits. Some are also noting the company's assets relative to its market cap.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices have recently seen significant volatility, driven by weather forecasts and fluctuating LNG exports. Community discussions revolve around whether a sustained rally is in store or if a pullback is imminent, considering high storage levels and production. Traders are actively debating potential entry points, technical indicators, and the impact of upcoming contract rollovers.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a combination of strong revenue growth news and speculation of a potential short squeeze, fueled by its low float. The community is actively comparing it to other Hong Kong-based stocks known for parabolic runs, while also discussing the company's shift towards AI-driven solutions and government contracts. High insider ownership is seen as a positive, though some traders are wary of the stock's volatile history.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe ($ADBE) is trending as investors debate its valuation and future amid AI competition, with some viewing it as undervalued while others express frustration with its performance. Discussions revolve around potential catalysts like upcoming earnings and possible acquisitions, as well as concerns about management and market sentiment. Many are closely watching key support levels, anticipating a potential rebound or further downside.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors digest recent earnings, upgrades from analysts, and a strategic partnership with AWS, with community members debating whether the stock is undervalued and poised for long-term growth. The focus remains on the company's position in cybersecurity and data resilience, along with its potential in AI. Some traders are taking profits, while others see the dip as a buying opportunity, expressing conviction in Rubrik's future and its role in protecting data amid rising cyber threats.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BTIG and H.C. Wainwright downgraded Vyne Therapeutics following topline results from the company’s Phase 2b trial of repibresib gel in nonsegmental vitiligo, which failed to meet both primary and secondary endpoints.BTIG analyst Julien Harrison downgraded the stock to ‘Neutral’ from ‘Buy’ and said the company will analyze the full dataset to guide next steps. He also noted that Vyne intends to seek a development and commercialization partner for repibresib.&nbsp;Harrison added that an update is expected in the coming weeks on both repibresib and VYN202, which is currently under partial clinical hold by the U.S. Food and Drug Administration.H.C. Wainwright analyst Joseph Pantginis also downgraded the stock to ‘Neutral’ from ‘Buy’ and removed the firm’s $4.5 price target, calling the trial outcome “a surprise” that “puts the company in a precarious position.”&nbsp;He said the firm will remain on the sidelines pending further clarity on repibresib, additional VYN202 data, or potential new asset acquisitions.Vyne said that the Phase 2b trial was a randomized, double-blind, vehicle-controlled study conducted at 45 sites across North America, enrolling 177 participants. The trial evaluated the once-daily topical administration of repibresib gel at 1%, 2%, and 3% concentrations compared to vehicle.&nbsp;The primary endpoint, defined as the proportion of patients achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index (F-VASI50) at week 24, was not met. The trial also missed a key secondary endpoint (F-VASI75).However, the company stated that the highest dose group showed a nominally statistically significant treatment effect in percent change from baseline (CFB) in both F-VASI and T-VASI scores at week 24.&nbsp;Vyne stated that the outcome was likely affected by a high vehicle effect and a higher-than-expected dropout rate in the active arms. As a result, the company has discontinued treatment in the extension phase and will terminate the trial.The company&nbsp;reported approximately $39.6 million in cash, cash equivalents, and investments as of June 30.&nbsp;Treatment-emergent adverse events (TEAEs) were more frequent in the repibresib arms, with application site pain being the most common. Eight subjects in the treatment group discontinued due to AEs, compared to none in the vehicle group. Most TEAEs were mild and resolved during the study.CEO David Domzalski said the company was disappointed by the outcome but remains confident in the potential of its InhiBET BET inhibitor platform.On Stocktwits, retail sentiment for Vyne was ‘extremely bullish’ late Wednesday amid&nbsp;an 11,800% surge in 24-hour message volume.One user said they went long on Vyne at&nbsp;$0.4189, calling the selloff part of the biotech cycle. “Every setback is a setup for a comeback,” they wrote, adding that while the vitiligo trial missed, the underlying science still showed promise.&nbsp;They also pointed to the FDA's recent move&nbsp;regarding the company’s psoriasis program and noted that Vyne has sufficient cash to operate into late 2026.<stembedurl>https://stocktwits.com/BulldogTheDip/message/623071473</stembedurl>Another user highlighted Vyne’s $39 million cash position, suggesting the stock could attract activist investors like Tang Capital Management. “If they step in, we could see a bounce,” the user wrote.<stembedurl>https://stocktwits.com/MadHatterTrades74/message/623051900</stembedurl><a href="https://stocktwits.com/symbol/VYNE">Vyne’s stock</a> has declined 88.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pharma stock. (Photo credit: Getty Images)

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

The company plans to seek a development and commercialization partner for repibresib and expects to provide an update on both repibresib and VYN202, which are currently under partial FDA clinical hold, in the coming weeks. 

Equity

Buy Rating for VYNE Therapeutics Amid Strong Financial Footing and Promising Clinical Trials

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on VYNE Therapeutics (VYNE Research Report). The associated price targe...

Buy Rating on VYNE Therapeutics: Promising Clinical Advancements and Market Potential

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on VYNE Therapeutics (VYNE Research Report), retaining the price target of $6.00...

Analyst Scoreboard: 4 Ratings For VYNE Therapeutics

Latest Ratings for VYNE
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.AssumesBuy May 2021HC Wainwright & Co.MaintainsBuy Oct 2020HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings for...

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company focused on developing proprietary...

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

VYNE Therapeutics Inc

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

VYNE
VYNE Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VYNE News

VYNEVYNE Therapeutics Inc